



## SHAYMAA EMAM ABBAS MOHAMED KASSAB

### University address

Department of Pharmaceutical Chemistry,  
Faculty of Pharmacy, Damanhour Univ.  
Galal Koreitam Square, Damanhour City 27.  
Zip Code: 22516  
Tel. +20(45)3368069, Fax. +20(45)3368069  
Email: shaymaakassab@yahoo.com  
shaymaa.kassab@pharm.dmu.edu.eg

### Home address

425 El-Nargess Buildings-5<sup>th</sup>  
settlement, North Teseen  
st.(3<sup>rd</sup> Floor, Apt 8), New  
Cairo 11835  
Cairo, Egypt  
Mobile. +20-100-5267-570

### **EDUCATIONAL QUALIFICATIONS**

- 1997-2002** B.Sc. in pharmaceutical sciences from the Faculty of Pharmacy, Helwan University, Cairo, Egypt
- 2002-2006** M.Sc. in pharmaceutical chemistry in "Synthesis of Some Novel Glycosides of Expected Chemotherapeutic Activity".  
Faculty of Pharmacy, Helwan University, Egypt.
- 2007-2009** Ph.D. in pharmaceutical chemistry in "Synthesis of Certain Indole Derivatives of Expected Biological Activity". Faculty of Pharmacy, Cairo University, Egypt.

### **SPECIAL TECHNICAL SKILLS**

1. Expertise in **Molsoft ICM 3.4-8c**, **MOE**, **LeadIT**, **MOE**, and **SeeSAR 9** programs, for docking of flexible ligand and molecular edited compounds into rigid protein involving the Windows operating system.
2. Expertise in operating **Nicolette FT/IR** and the **Schimidzu spectrophotometer**.
3. Expertise in operating the **CombiFlash**<sup>®</sup> Automated purification system.
4. Expertise in operating automated **Bruker 400 MHz NMR** and **Varian NMR 400** spectrophotometers.
5. Good at operating **the Amazon Ion Trap ESI Mass Spectrophotometer**.

### **ACADEMIC EXPERIENCES**

- 2002-2007** Teaching Assistant (B.Sc.) for the practical sessions of Physical, Organic, and Pharmaceutical Chemistry courses, Faculty of Pharmacy, Misr International University.

- 2007-2009** Teaching Assistant (M.Sc.) of Pharmaceutical Chemistry, Faculty of Pharmacy, Misr International University.
- 2009-2011** Assistant professor of Medicinal Chemistry.  
Supervisor of the practical Pharmaceutical Chemistry courses in the Faculty of Pharmacy, Misr International University.  
Executive member in the Faculty's **Curriculum Committee**.  
Executive member in the Faculty's **Exam Assessment** and **Examination Control Committee**.
- 2010-2014** Lectured pharmacy students in Pharmaceutical Chemistry and Drug Design courses.  
Supervisor of one Master's thesis entitled "**Molecular design and synthesis of histone deacetylase inhibitors as antineoplastic agents**" – awarded the degree.
- 2011-2019** Assistant professor of Medicinal Chemistry, Faculty of Pharmacy, Damanhour University.  
Lectured Pharmacy students in Medicinal Chemistry I, II, and III courses and Drug design to senior students.
- 2016-2018** Supervisor of one Master's thesis entitled "**Design, Synthesis, and Evaluation of the antioxidant capacity of some new indole derivatives**" – awarded the degree.
- 2016-2022** Supervisor on the Ph.D. thesis entitled "**Design, Synthesis and Biological Evaluation of novel indazole compounds with potential therapeutic activity**" – awarded the degree.
- 2018- 2022** Supervisor on Master's theses entitled "**Design, synthesis and biological evaluation of some thiazole derivatives of potential therapeutic activity**"-awarded the degree; "**Design and Synthesis of Some New Heterocyclic Compounds as Potential Anticancer Agents**" – awarded the degree.
- 2019 – 2025** Associate Professor of Medicinal Chemistry
- 2020 – present** Principal Supervisor on Master's thesis entitled "**Design, synthesis and Biological Evaluation of Diverse Chemical Structures Having Selective HDAC6 Inhibiting Activity**"-under study; "**Different Drug Design**

**Approaches to Generate HDAC6 Inhibitors with Enhanced Potency and Selectivity”** – under study.

**2023 – present** Principal Supervisor on Master's thesis entitled “**Design, synthesis, and Biological Evaluation of New Tetrahydrocarbazole Derivatives**” – under study

**2025-Present** Professor of Medicinal Chemistry

### ***MEMBERSHIP IN INTERNATIONAL ORGANIZATIONS***

Member of the American Chemical Society (2017)

### ***PHARMACY PRACTICE EXPERIENCES***

**2001-2002** Working as a trainee in Quality Assurance, Process Control, Production, Packaging, and Quality Control departments of **Sanofi Company of Pharmaceuticals**.

**2002-2003** Administrator in a private community pharmacy.

### ***ACADEMIC ACTIVITIES & Training***

**2008** Guest in a workshop belonging to South Carolina University about "Pharmacy Education" at Misr International University.

**2012** Trainee in workshops entitled: "**International Publishing**" and "**Communication and Rhetorical Techniques**", organized by the DAAD office in Cairo

**2013** Guest in a seminar on "**Quality Assurance in Research - Ethics and Science**", organized by DAAD and ANQAHE.

**2014** Presented a poster in the computer-aided drug design (CADD) Symposium entitled “**Small molecule BCL6 inhibitors for the treatment of Diffuse Large B-Cell Lymphoma**” at the University of Maryland in Baltimore, School of Pharmacy -Pharmaceutical Sciences Department (USA).

**2016** Presented a poster in the College of Pharmacy Colloquium 2016 entitled “**Design, Synthesis, *In silico* Study and Biological Evaluation of Flavin Analogs as Novel Selective and Potent Antitumor Agents**” at Texas A&M University, College of Pharmacy – Pharmaceutical Sciences Department (USA).

- 2016** Invited to attend Lowenthal Symposium, March 11, 2016, at Virginia Commonwealth University, School of Pharmacy – Medicinal Chemistry department (USA).
- 2017** Invited speaker to German-Egyptian Network for Innovation and Development (GENID) 2017, Alexander von Humboldt kolleg.
- 2017** Accepted speaker at Zewail City Conference & Exhibition on Biomedical Sciences, Giza, Egypt.
- 2017** Executive head of Grants and International Cooperation Office (**GICO**) – Damanshour University.
- 2017** Founder of *in silico* design dry laboratory, set up with official license of LeadIT software purchased from a German company to serve research and teaching work at the Faculty of Pharmacy – Damanshour University.
- 2018** Accepted oral presenter and poster exhibitor at Drug Discovery Chemistry Conference, San Diego, California, USA.
- 2018** Trainee in a workshop entitled “**Effective ICT policies for managing E-learning in higher education**” organized by the DAAD office in Cairo.
- 2018** Trainee in a workshop entitled “**Training of the Trainer (TOT)**” organized by the DAAD office in Cairo.
- 2019** Trainee in a workshop entitled “**Statistical Analysis using SATA I**” organized by the DAAD office in Cairo.  
 Trainee in a workshop entitled “**Introduction to Patents**” organized by Derwent (A Clarivate Analytics company) and the Egyptian Academy of Scientific Research & Technology.  
 Trainee in a workshop entitled “**Research and Development Strategies**” organized by Derwent (A Clarivate Analytics company) and the Egyptian Academy of Scientific Research & Technology.
- 2020** Trainee in a workshop entitled “**Logical Manuscript Structure**” & “**Effective Post-submission Strategies**” organized by Nature Research Academies and Egyptian Knowledge Bank.  
 Presenter in a live webinar entitled “**Using Egyptian Knowledge Bank to choose competent MSc/PhD supervisor**” hosted by Egyptian Researchers Network.

- 2021** Trainee in a “**Journal Editor 2**” workshop organized by Springer Nature Research Academies and Egyptian Knowledge Bank.  
Live Webinar organizer entitled “**Expanding drug development using GD3, a consortium of preclinical CROs**” in coordination with Genesis Biotechnology Group in New Jersey, USA.  
Live Webinar organizer entitled “**Metabolism and Mitochondria in Health and Disease**” in coordination with Children’s Cancer Hospital 57357.

### ***RESEARCH ACTIVITIES***

- 2014** Visiting scholar at the University of Maryland in Baltimore, School of Pharmacy -Pharmaceutical Sciences Department via a personal grant.
- 2016** Visiting scholar at Virginia Commonwealth University, School of Pharmacy – Medicinal Chemistry department via a scientific mission offered by the cultural affairs and missions sector of the Ministry of Higher Education in Egypt.
- 2016** Visiting scholar at Texas A&M University, College of Pharmacy – Pharmaceutical Sciences department via a scientific mission offered by the cultural affairs and missions sector of the Ministry of Higher Education in Egypt.
- 2017** Certified **Outstanding Reviewer** of the European Journal of Medicinal Chemistry.
- 2018** **Principal investigator** of a research project (Young Researcher) entitled “Design and Synthesis of Novel Selective Estrogen Receptor Modulators,” funded by **Science and Technology Development Fund (STDF)-ID: 25717**.
- 2019** Assigned editor to book series “**Frontiers in bioactive compounds**” – Bentham Science.
- 2023** Official reviewer of Frontiers in Chemistry.  
Certified reviewer of ACS publisher (Journal of Medicinal Chemistry and ACS Omega)  
Official reviewer of the Elsevier publisher (Bioorganic Chemistry, EJMEC)  
Official reviewer of the Springer Nature publisher (Journal of Molecular Diversity)

### ***SOCIETAL AND NON-SOCIETAL ACTIVITIES***

**2016** Team coach of Pharmacy-undergraduate students in the national campaign of “Egypt free from virus C”.

**2018** Instructor and trainer of outstanding children joining “Children’s University”.

### **LANGUAGES**

- Native language: Arabic
- Excellent command of Reading, Writing, and Speaking English (certified by American University in Cairo and *iBT*-TOEFL).

### **PERSONAL INFORMATION**

- *Date of Birth*: 01/09/1980
- *Marital Status*: Single
- *Nationality*: Egyptian

### **REFEREE NAMES**

**1. Prof. D.Sc. Galal Elgemeie** (*Supervisor*)

Professor of Organic Chemistry, Faculty of Science, Helwan University.

E-mail: elgemeie@yahoo.com

**2. Prof. D.Sc. Hussein El-Subbagh**

Professor of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University.

E-mail: subbagh@yahoo.com

**3. Prof. Dr. Kamelia Mahmoud Amin** (*Supervisor*)

Professor of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.

E-mail: cameliaamin@yahoo.com

**4. Prof. Dr. Khaled Abouzid**

Professor of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University.

E-mail: abouzid@yahoo.com

**5. Prof. Dr. Ashraf Abadi**

Professor of Pharmaceutical Chemistry, Faculty of Pharmacy, German University in Cairo.

E-mail: ashraf.abadi@guc.edu.eg

**6. Prof. Dr. Sherief Khalifa**

Dean & Professor of Pharmacognosy, Faculty of Pharmacy, Dubai Medical University (UAE).

E-mail: [khalifa.sherief@gmail.com](mailto:khalifa.sherief@gmail.com)

### **PAST RESEARCH & ACHIEVEMENTS**

- *The subject of M.Sc. research work was entitled:*

## “Synthesis of Some Novel Glycosides of Expected Chemotherapeutic Effect”

The main goal of my M.Sc. work was to develop new thioglycosides featuring unusual aglycones that could be beneficial in chemotherapy due to their role as nucleoside analogs.

### **1. Synthesis of pyridine thioglycosides:**

This section discusses silylation and potassium salt methods for effective glycosylation of different pyridine-2(1H)-thione derivatives with ribofuranose pentaacetate and various acetobromosugars.

### **2. Synthesis of quinoline thioglycosides:**

In this part, potassium salt formation of various 4-Aryl-3-cyano-7,7-dimethyl-5-oxo-1,2,5,6,7,8-hexahydroquinoline-2-thione derivatives was used for efficient glycosylation with different acetobromosugars to obtain the corresponding thioglycosides.

### **3. Synthesis of acrylonitrile thioglycosides**

This section covered the synthesis of various acrylonitrile thioglycosides using one-pot reaction conditions to achieve a high yield of this unusual nucleoside analog.

Biological testing of the resulting thioglycosides as antimicrobial agents showed that thioglycosides, as a class of nucleoside analogs, have promising antibacterial and antifungal activities.

#### ➤ ***The subject of my Ph.D. work was entitled:***

## “Synthesis of Certain Indole Derivatives of Expected Biological Activity”

The goal of my Ph.D. research was to study the antimicrobial activity of various nucleoside analogs that incorporate different indole moieties. This was inspired by the history of indole as a chemotherapeutic agent, and I found it interesting to investigate the antiviral and antibacterial effects of the newly synthesized indole derivatives and indole-nucleoside analogs. Each research hypothesis was supported by molecular modeling and docking studies of the resulting compound series using Molsoft ICM 3.4-8C and ChemOffice 8-Ultra-2004 programs. The main achievements can be summarized as follows:

### **1. Synthesis of 2-arylindolylpyrazoles:**

The first task of the present investigation was to study derivatives of 2-arylindolylpyrazoles as safe and broad-spectrum antibacterial agents. Therefore, we chose these hybrids based on the observation that indole derivatives exhibit antibacterial activity against gram-positive bacterial strains, especially those

involving 2-phenylindolylpyrroledione and many compounds containing a pyrazole ring.

## **2. Synthesis of 9-glycosyl-4,9-dihydropyrano[3,4-b]indole-1(3H)-ones**

This part involved introducing different glycones to the 4,9-dihydropyrano[3,4-b]indole-1(3H)-one derivative using silver oxide catalysis.

## **3. Synthesis of 1H-indole-2,3-dione-3-thiosemicarbazone ribonucleosides:**

This part aimed to design novel nucleoside analogs because of the well-known biological activity of thiosemicarbazones, combined with the reported broad-spectrum chemotherapeutic properties of 1H-indole-2,3-dione (isatin) and its ribonucleoside derivatives.

***The project that I have been engaged in as a postdoctoral research fellow in the School of the University of Maryland in Baltimore is entitled:***

“Design and synthesis of small molecule inhibitors of diffused B-cell lymphoma 6 (BCL6)”

I achieved the synthesis of over 25 final small molecules from 2 different scaffolds within 4 months, which are currently undergoing biological testing for their BCL6 inhibitory activity. One of my designed compounds demonstrated ten times greater potency than the previously discovered lead compound and was patented in WO2008066887A2.

## ***PUBLICATIONS***

1. Kassab, S. E.; Hegazy, G. H.; Eid, N. M.; Amin, K. M.; El-Gendy, A. A., **Synthesis of 1H-indole-2,3-dione-3-thiosemicarbazone Ribonucleosides as Antibacterial Agents**", *Nucleosides Nucleotides Nucleic Acids*, 2010, 29, 72 – 80.
2. Kassab, S. E.; Hegazy, G. H.; Eid, N. M.; Amin, K. M.; El-Gendy, A. A., **Synthesis of New 9-glycosyl-4,9-dihydropyrano[3,4-b]indole-1(3H)-ones as Antibacterial Agents**" *Nucleosides Nucleotides Nucleic Acids* 2011, 30, 991 – 998.
3. Abdel-Atty, M. M.; Farag, N. A.; Kassab, S. E.; Serya, R. A. T., Abouzid, K. A. M., **Design, Synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as histone deacetylase inhibitors**, *Bioorganic Chemistry* 2014, 57, 65-82.
4. Xinhua, H.; Kassab, S. E.; Geoffery, H.; Xue, F., **Base-catalyzed one-step synthesis of 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines**, *Tetrahedron Letters* 2015, 56, 1034-1037.
5. Fatahala, S. S.; Shalaby, E. A.; Kassab, S. E.; Mohamed, M. S., **A Promising Anti-Cancer and Anti-Oxidant Agents Based on the Pyrrole and Fused Pyrrole:**

**Synthesis, Docking Studies and Biological Evaluation, *Anticancer Agents in Medicinal Chemistry* 2015, 15(4), 517-526.**

6. **Kassab, S. E.\*; Khedr, M. A.; Aly, H. I.; Abdallah, M. M., Discovery of New Indomethacin-based analogs with Potentially Selective Cyclooxygenase-2 Inhibition and Observed Diminishing to PGE2 activities, *European Journal of Medicinal Chemistry* 2017, 141, 306-321.**
7. **ElBordiny, H. S., El-Miligy, M. M.; Kassab, S. E.\*; Daabees, H.; El-Hawash, S. A. M; Ali, W. A. M., Design, synthesis, biological evaluation and docking studies of new 3-(4,5-dihydro-1H-pyrazol/ioxazol-5-yl)-2-phenyl-1H-indole derivatives as potent antioxidants and 15-lipoxygenase inhibitors, *European Journal of Medicinal Chemistry* 2018, 145, 594-605.**
8. **Kassab, S. E.\*; Mowafy, S.; Alserw, A. M.; Seliem, J. A.; l-Naggar, S. M.; Omar, N. N.; Awad, M. M., Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma, *Journal of Enzyme Inhibition and Medicinal Chemistry* 2019, 34, 1062-1077.**
9. **Rashad, A. Y.; Kassab, S. E.; Daabees, H. G.; Moneim, A. E. A.; Rostom; S. A. F., Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies, *Bioorganic Chemistry*, 2021, 113, 104948.**
10. **Kassab, S. E.\*; Mowafy, S., Structural basis of selective human indoleamine-2, 3-dioxygenase 1 (hIDO1) inhibition, *ChemMedChem*, 2021, 16 (20), 3149-3164.**
11. **Mahmoud A Ragab, Mohamed Elagawany, Hoda Daabees, Al-Shaimaa F Ahmed, Eman M Awad, Cyrielle Billon, Bahaa Elgendy, Khaled AM Abouzid\*, Shaymaa E Kassab\*, Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity, *Bioorganic Chemistry*, 2022, 119, 105554.**
12. **Nada H El-Dershaby, Soad A El-Hawash, Shaymaa E Kassab, Hoda G Dabees, Ahmed E Abdel Moneim, Ibrahim A Abdel Wahab, Mohammad M Abd-Alhaseeb, Mostafa MM El-Miligy, Rational design of biodegradable sulphonamide candidates treating septicaemia by synergistic dual inhibition of COX-2/PGE2 axis and DHPS enzyme, *Journal of enzyme inhibition and medicinal chemistry*, 2022, 37, 1737-1751.**
13. **Ahmed I Khodair, Shaymaa E Kassab, Nabila A Khedr, Asmaa M Fahim, Synthesis of novel d- $\alpha$ -galactopyranosyl-l-seryl/l-threonyl-l-alanyl-l-alanine as useful precursors of new glycopeptide antibiotics with computational calculations studies, *Carbohydrate Research*, 2022, 514, 108546.**

14. Mostafa M Elbadawi, Ahmed I Khodair, Mohamed K Awad, **Shaymaa E Kassab**, Mohammed T Elsaady, Khaled RA Abdellatif, **Design, synthesis and biological evaluation of novel thiohydantoin derivatives as antiproliferative agents: A combined experimental and theoretical assessments**, *Journal of Molecular Structure*, 2022, 1249, 131574.
15. Nada H El-Dershaby, Soad A El-Hawash, **Shaymaa E Kassab**, Hoda G Daabees, Ahmed E Abdel Moneim, Mostafa MM El-Miligy, **Rational Design and Synthesis of New Selective COX-2 Inhibitors with In Vivo PGE2-Lowering Activity by Tethering Benzenesulfonamide and 1,2,3-Triazole Pharmacophores to Some NSAIDs**, *Pharmaceuticals*, 2022, 15, 1165.
16. Ahmed I. Khodair\*, Salwa M. El-Hallouty, Brittnee Cagle-White, May H. Abdel Aziz, Mahmoud Kh Hanafy, Samar Mowafy, Nadia M. Hamdy\*, **Shaymaa E. Kassab\***, **Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma**, *European Journal of Medicinal Chemistry* 2024, 265, 116049.
17. Amr S Abouzied, Bahaa Alshammari, Hayam Kari, Bader Huwaimel, Saad Alqarni, **Shaymaa E Kassab**, **AI-DPAPT: a machine learning framework for predicting PROTAC activity**, *Molecular Diversity*, 2024, 1-13.
18. **Kassab, S. E.\***, **A new computational cross-structure-activity relationship (C-SAR) approach applies to a selective HDAC6 inhibitor dataset for accelerated structure development**, *Computers in Biology and Medicine*, 2025, 192, 110169.
19. Bader Huwaimel <sup>a b</sup>, Amr S. Abouzied <sup>a b</sup>, Abdul-Hamid Emwas <sup>c</sup>, Al-Shaimaa F. Ahmed <sup>d</sup>, Mohamed K.S. El-Nagar <sup>e</sup>, Hamdoon A. Mohammed <sup>f</sup>, Nader M. Alrashidi <sup>g</sup>, Marwan A. Alrashidi <sup>g</sup>, Rakan E. Alshammari <sup>g</sup>, Abdullelah Y. Albladi <sup>g</sup>, Saad Alqarni <sup>a</sup>, **Shaymaa E. Kassab <sup>h\*</sup>**, **Precise structure manipulation of selective estrogen receptor modulators led to first-in-class thiophene-3-benzamide derivatives as potential ER-antagonists without uterotrophic activity**, *Bioorganic Chemistry*, 2025, 161, 108512.
20. Nadia M. Hamdy\*, Eman F. Sanad<sup>1</sup>, **Shaymaa E. Kassab\***, Merhan Essam, Monica A. Guirguis, Emad B. Basalious, Ahmed S. Sultan, **Chembioinformatics data-driven Engineering of Exosomal Cargo Vehicle for Telmisartan and Pioglitazone Targeted Delivery for Treatment of Non-Small Cell Lung Cancer**, *Scientific Reports*, 2025, 15, 25166.

### **BOOKS AND BOOK CHAPTERS**

**Kassab, S. E., Indomethacin from anti-inflammatory to anticancer agent**, a book chapter in Medicinal Chemistry Book (2018), IntechOpen, Doi: 10.5772/intechopen.79677.

**Kassab, S. E., Medicinal Chemistry I, Cardiovascular Agents and Diuretics, Deposit No. 20020/2018.**

**Kassab, S. E., Medicinal Chemistry II, Hormones, Oral hypoglycemics, Anti-histamine, and Ca homeostatic agents, Deposit No. 20021/2018.**

**Kassab, S. E., Medicinal Chemistry III, Antibiotics and Chemotherapeutic Agents, Deposit No. 20022/2018.**

**Kassab, S. E., Drug Design, New aspects and approaches for successful design toward drug discovery and drug development, Deposit No. 20023/2018.**

### **CONFERENCE**

1. The Pharmaceutical Society of Egypt 31<sup>st</sup> Conference of Pharmaceutical Sciences (2008) 23<sup>rd</sup>-25<sup>th</sup> December, Cairo, Egypt.
2. College of Pharmacy Colloquium 2016 (poster presenter), Texas A&M University, College Station, Texas – United States of America.
3. German-Egyptian Network for Innovation and Development (GENID), 2017, Alexander von Humboldt kolleg (Oral presenter) in Cairo, Egypt.
4. Zewail City Conference & Exhibition on Biomedical Sciences (Oral presenter), 2017, Giza, Egypt.
5. Cambridge Healthtech Institute's 13<sup>th</sup> Annual Drug Discovery Chemistry (Oral presenter), 2018, San Diego, California.
6. 1<sup>st</sup> International Conference of Pharmaceutical Sciences (Guest speaker), 2018, Menofia University, Egypt.
7. International Cairo Science Forum (Oral presenter), 2019, Alexander von Humboldt kolleg, Cairo, Egypt.
8. National Committee of Women in Science Conference (Speaker), 2020, “Woman’s role for achieving the sustainable development goals– Egypt 2030.
9. Cambridge Healthtech Institute's 15<sup>th</sup> Annual Drug Discovery Chemistry (Oral presenter), 2020, San Diego, California.
10. BGICC 2021, the 13<sup>th</sup> Breast- Gynecological & Immunooncology International Cancer Conference (Attendee)
11. Cambridge Healthtech Institute's 16<sup>th</sup> Annual Drug Discovery Chemistry (Attendee), 2021, San Diego, California.

12. BGICC 2022, the 14<sup>th</sup> Breast- Gynecological & Immunooncology International Cancer Conference (Speaker)

13. National Research Center, 7<sup>th</sup> International conference of pharmaceutical and drug industries, 13-14<sup>th</sup> March 2023 (Keynote Speaker).

**Official websites:**

Scopus:

<https://www.scopus.com/authid/detail.uri?authorId=56364523100>

Google Scholar:

<https://scholar.google.com.eg/citations?user=n1I4Im0AAAAJ&hl=en#>

WOS:

<https://www.webofscience.com/wos/author/record/E-4255-2019>

ORCID:

<https://orcid.org/my-orcid?orcid=0000-0002-4789-2662>

Researchgate:

<https://www.researchgate.net/scientific-contributions/Shaymaa-E-Kassab-2133418544>